Cure Pharmaceutical Holding Corp   (MKNT)
Other Ticker:  
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare

Cure Pharmaceutical Holding 's



MKNT Sales vs. its Competitors Q1 2020

Comparing the results to its competitors, Cure Pharmaceutical Holding reported Total Revenue increase in the 1 quarter 2020 by 275.84 % year on year.
The revenue growth was below Cure Pharmaceutical Holding 's competitors average revenue growth of 275.84 %, recorded in the same quarter.

List of MKNT Competitors

With net margin of 730.71 % company reported lower profitability than its competitors.

More on MKNT Margin Comparisons

Revenue Growth Comparisons

Net Income Comparison

Cure Pharmaceutical Holding Corp achieved net profit of $2 millions compare to net loss of $-10 millions recorded in same quarter a year ago.

<<  More on MKNT Income Comparisons

Cure Pharmaceutical Holding 's Comment on Competitors and Industry Peers

We face competition from other companies, academic institutions, governmental agencies and other public and private research organizations for collaborative arrangements with pharmaceutical and biotechnology companies, in recruiting and retaining highly qualified scientific and management personnel and for licenses to additional technologies. Many of our competitors, including Monosol, BioDelivery Sciences International, IntelGenx and LTS Lohmann, will have substantially greater financial, technical and human resources than we have. Our success will be based in part on our ability to build, obtain regulatory approval for and market acceptance of, and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy.

The OTF manufacturing industry is relatively new, having only emerged over the last ten years. Although currently there are just a handful of current players within this industry, we expect that we will be subject to competition from numerous other companies that currently operate or are planning to enter the markets in which we compete. To date, among manufacturers of OTF, some medications that either are or have been available by OTF manufacturers in the marketplace include:

Zuplenz (the first oral soluble film approved by the FDA as a prescription medication)

Benadryl (diphenhydramine product and anti-histamine used for allergies and mild sedative)

Gas-X (simethicone product for bloating, gas, and gastrointestinal complaint)

Melatonin PM (hormonal product sold as a "dietary supplement" marketed for insomnia)

Orajel Kids (benzocaine product for dental pain)

Suboxone (buprenorphine and naloxone fixed dosage combination product for opioid addiction)

Subutex (buprenorphine product for opioid addiction)

Sudafed (phenylephrine or pseudoephedrine product for nasal congestion)

TheraFlu (combination product of pain reliever, anti-pyretic and decongestant)

Triaminic (children's anti-tussive product)

The barriers to enter this market are the “know how’s” of developing and formulating consumer desired products which taste great. Also, the high cost of entry by companies who have no expertise in the market makes entry by competitors risky since the technology to develop product is expensive and proprietary. The key factors affecting the development and commercialization of our drug delivery products are likely to include, among other factors:

The safety and efficacy of our products;

The relative speed with which we can develop products;

Generic competition for any product that we develop;

Our ability to defend our existing intellectual property and to broaden our intellectual property and technology base;

Our ability to differentiate our products;

Our ability to develop products that can be manufactured on a cost effective basis;

Our ability to manufacture our products in compliance with cGMP and any other regulatory requirements; and

Our ability to obtain financing.

In order to establish ourselves as a viable industry partner, we plan to continue to invest in our research and development activities and in our manufacturing technology expertise, in order to further strengthen our technology base and to develop the ability to manufacture our CureFilm™ products ourselves, at competitive costs. Our failure to compete effectively could have a material adverse effect on our business.

*Market share is not actual measurement, only performance comparison of companies which report and operate within the same segment.

MKNT's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

Cure Pharmaceutical Holding Corp MKNT 0 1 12 1
SUBTOTAL 0 1 12 1


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

CCX's Profile

Stock Price

CCX's Financials

Business Description


Charts & Quotes

CCX's News


CCX's Competitors

Customers & Markets

Economic Indicators

CCX's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries





At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071